Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBy now, the industry is quite familiar with how COVID-19 impacted the clinical development landscape. Working through the pandemic challenge is one thing. But, as an industry, we know roadblocks are always possible elsewhere in the [clinical research/clinical trial/something like that] process. Having a strong, adaptable site strategy is a critical component of clinical development for sponsors and site teams to maintain trial continuity.
As part of a comprehensive site strategy, the pandemic has taught us how critical an ongoing relationship with sites is to the trial process. Sites and their patients are valued partners, where engagements can build beyond one-off programs, potentially going into other therapeutic areas and more. In facing roadblocks or to increase efficiencies, we’ve long needed existing relationships with sites to help sponsors and clinical research organization (CRO) partners adapt strategies quickly for trial continuity.
When mapping out how to potentially work with each site in their network as needs arise, sponsors and CROs need to consider classifying sites based on several factors. This way diverse “go-to” site networks are ready to activate, and sponsors can evaluate their site options as they design and build clinical trial programs.
As some countries experience resurgences in COVID-19, sponsors need to stay ready as sites may temporarily close or need to make quick adjustments.
As part of a proactive strategy, sponsors should keep an up to date list of which sites can or cannot be included in trial programs. This practice is vital for addressing study challenges and maintaining diverse partnerships that can help match trial needs with individual site capabilities.
IQVIA’s site network structure categorizes relationships in key groups of elite, therapeutic, and specialty sites. For elite sites that have a long-standing relationship with IQVIA, these networks often work across multiple therapeutic areas or in single, high-volume therapeutic spaces, and aim to surpass industry benchmarks to meet trial requirements. At IQVIA, these sites typically leverage our tech-enabled solutions and data insights to meet our customers’ key study deliverables.
For therapeutic and specialty sites, IQVIA may partner with a research institution or site that has a proven track record of quality performance in managing studies and meeting anticipated needs within varying therapeutic spaces. Working with expert sites and investigators in specialized fields (e.g., rare diseases, cell and gene therapy, etc.) is key to ensure the appropriate capabilities are in place to meet the trial and patient needs.
In realizing that sites are partners in the process, CROs need to have support services in place to help sites continue recruiting patients when the trial hits a roadblock such as a pandemic.
For example, in the initial months of the pandemic, patient recruitment was a significant concern for sponsors and CROs, especially as patient interest in trial participation increased. To not miss that opportunity, sponsors and CROs needed to step in and create another way—outside of traditional investigator-led recruitment—to reach patients and connect them to trials. At IQVIA, we relied on proprietary healthcare data assets and modeling algorithms using artificial intelligence and machine learning to create a direct-to-patient recruitment model. We first worked through partner sites with large, eligible patient populations and then widened the search beyond the site to rapidly recruit patients. We launched targeted, multi-channel campaigns (e.g., social media, pharmacies, labs, patient communities, etc.) to raise awareness of trials in local markets.
As sites reopened and interested patients were again ready to participate in trials, sponsors and CROs needed to help keep on track sites that were already behind in trial timelines as a result of limited site staff and resources. To avoid further enrollment delays, IQVIA re-engaged furloughed site staff using sponsor funding, temporarily designating that staff as part of our global site network infrastructure. It was dually beneficial as sites could reduce onboarding time while bringing back employees who knew the trial protocols well.
Future challenges are unknown to us, but we know that patient needs are only growing, making site relationships and related long-term yet adaptive, agile strategies crucial in our work as an industry to bring therapies to market.
Decrease clinical development costs and increase study quality using our global functional resources and flexible services, and get more value from your R&D spend.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
